（1） 国家自然科学基金委员会, 面上项目, 81972344, FASN调控VEGF-A可变剪切对脑胶质瘤着床转移和侵袭机制研究, 2020-01至2023-12, 55万元, 在研, 主持。

（2） 北京市自然科学基金-市教委联合项目, 北京市教委科技计划重点项目, 基金号, 新型溶瘤病毒ON-01治疗恶性脑胶质瘤的机制研究, 2020-01至2020-12, 80万元, 在研, 主持。

（3） 北京市健康委员会, 首都卫生发展科研专项-重点攻关项目, 首发2020-1-1071, 新型溶瘤病毒治疗复发恶性脑胶质瘤安全性及有效性临床研究, 2020-01至2022-12, 70万元, 在研, 主持。

（4） 国家自然科学基金委员会, 面上项目, 81672478, TTDR双调控溶瘤性HSV-1工程化间充质干细胞治疗脑胶质瘤研究, 2017-01至2020-12, 55万元, 结题, 主持。

（5） 北京市自然科学基金委员会, 重点项目, 7151002, 新型耦合VP22-CD基因载体构建及其对胶质瘤作用研究, 2015-01至2018-12, 65万元, 结题, 主持。

（6） 国家自然科学基金委员会, 面上项目, 81372354, 脑恶性胶质瘤微血管内皮和血管拟态形成机制及靶向治疗研究, 2014-01至2017-12, 70万元, 结题, 主持。

（7） 北京市教育委员会, 科研基地平台建设, PXM2014_014226_000005, 生物医用材料北京实验室, 2014-01至2024-12, 500万元, 在研, 主持。

论文发表（近五年）：

1.Zhu GD, Zhang JW, Zhang Q, Jin GS, Su XD, Liu SS, Liu FS: Enhancement of CD70-specific CAR T treatment by IFN-gamma released from oHSV-1-infected glioblastoma. Cancer Immunol Immun 2022.

2.Zhang Q, Zhang J, Wang P, Zhu G, Jin G, Liu F: Glioma-associated mesenchymal stem cells-mediated PD-L1 expression is attenuated by Ad5-Ki67/IL-15 in GBM treatment. Stem cell research & therapy 2022, 13(1):284.

3.Mi R, Ji J, Zhang M, Zhang J, Li M, Hu Y, Liu F: Establishment of the glioma polyploid giant cancer cell model by a modified PHA-DMSO-PEG fusion method following dual drug-fluorescence screening in vitro. J Neurosci Methods 2022, 368:109462.

4.Zhu G, Zhang Q, Zhang J, Liu F: Targeting Tumor-Associated Antigen: A Promising CAR-T Therapeutic Strategy for Glioblastoma Treatment. Front Pharmacol 2021, 12:661606.

5.Wang Q, Zhang J, Fang S, Wang J, Han X, Liu F, Jin G: P4HA1 Down-Regulation Inhibits Glioma Invasiveness by Promoting M1 Microglia Polarization. Onco Targets Ther 2021, 14:1771-1782.

6.Liu S, Zhang J, Fang S, Zhang Q, Zhu G, Tian Y, Zhao M, Liu F: Macrophage polarization contributes to the efficacy of an oncolytic HSV-1 targeting human uveal melanoma in a murine xenograft model. Exp Eye Res 2021, 202:108285.

7.Dong CY, Hong S, Zheng DW, Huang QX, Liu FS, Zhong ZL, Zhang XZ: Multifunctionalized Gold Sub-Nanometer Particles for Sensitizing Radiotherapy against Glioblastoma. Small 2021, 17(5):e2006582.

8.Zhou Y, Liu Y, Zhang J, Yu D, Li A, Song H, Zhang W, Davis D, Gilbert MR, Liu F et al: Autocrine BMP4 Signaling Enhances Tumor Aggressiveness via Promoting Wnt/beta-Catenin Signaling in IDH1-mutant Gliomas. Transl Oncol 2020, 13(2):125-134.

9.Zhang Q, Zhang J, Tian Y, Zhu G, Liu S, Liu F: Efficacy of a novel double-controlled oncolytic adenovirus driven by the Ki67 core promoter and armed with IL-15 against glioblastoma cells. Cell Biosci 2020, 10:124.

10.Zhang Q, Liu F: Advances and potential pitfalls of oncolytic viruses expressing immunomodulatory transgene therapy for malignant gliomas. Cell Death Dis 2020, 11(6):485.

11.Zhang J, Fang S, Song W, Zhang B, Fan W, Jin G, Liu F: Biological Characterization and Therapeutics for Subscalp Recurrent in Intracranial Glioblastoma. Onco Targets Ther 2020, 13:9085-9099.

12.Mi R, Fan W, Ji J, Dong C, Jin G, Liu F: The enhanced efficacy of herpes simplex virus by lentivirus mediated VP22 and cytosine deaminase gene therapy against glioma. Brain Res 2020:146898.

13.Liu S, Zhang J, Fang S, Su X, Zhang Q, Zhu G, Zhu L, Zhao M, Liu F: Antitumor efficacy of oncolytic HSV-1 expressing cytosine deaminase is synergistically enhanced by DPD down-regulation and EMT inhibition in uveal melanoma xenograft. Cancer Lett 2020, 495:123-134.

14.Hu S, Dong C, Wang J, Liu K, Zhou Q, Xiang J, Zhou Z, Liu F, Shen Y: Assemblies of indocyanine green and chemotherapeutic drug to cure established tumors by synergistic chemo-photo therapy. J Control Release 2020, 324:250-259.

15.Dong C, Zhou Q, Xiang J, Liu F, Zhou Z, Shen Y: Self-assembly of oxidation-responsive polyethylene glycol-paclitaxel prodrug for cancer chemotherapy. J Control Release 2020, 321:529-539.

16.Dong C, Zhang J, Fang S, Liu F: IGFBP5 increases cell invasion and inhibits cell proliferation by EMT and Akt signaling pathway in Glioblastoma multiforme cells. Cell Div 2020, 15:4.

17.Zhang JW, Cui YB, Chen H, Huang BR, Liu FS: eIF4A1 is Associated With TrkA and Inhibits TrkA Polyubiquitination. Progress in Biochemistry and Biophysics 2019, 46(8):812-822.

18.Fan WH, Shao MY, Zhang JW, Jin GS, Xu FJ, Liu FS: A Hybrid Nanovector of Suicide Gene Engineered Lentivirus Coated with Bioreducible Polyaminoglycosides for Enhancing Therapeutic Efficacy against Glioma (vol 29, 1807104, 2019). Adv Funct Mater 2019, 29(11).

19.Zhang Y, Jin G, Zhang J, Mi R, Zhou Y, Fan W, Cheng S, Song W, Zhang B, Ma M et al: Overexpression of STAT1 suppresses angiogenesis under hypoxia by regulating VEGFA in human glioma cells. Biomed Pharmacother 2018, 104:566-575.

专利：1.TSPO在治疗脑胶质瘤中的应用及重组单纯疱疹病毒及其制备方法和应用. 北京市神经外科研究所、北京神源德生物科技有限公司. 刘福生，李小鹏，田超，张俊文.(专利号：ZL201711251406.7)；申请日：2017-12-01；授权日：2019-03-05

2.预测或诊断脑恶性胶质瘤术后复发的生物标志物组合及其应用和试剂盒. 北京市神经外科研究所. 刘福生，张俊文，苏晓东，张梦梦，金贵善，米蕊芳.(专利号：ZL201810987576.X)；申请日：2018-08-28；授权日：2021-07-13

3.一种人脑胶质瘤细胞系建立方法及其应用. 北京市神经外科研究所. 张俊文，刘福生，方胜，宋文杰. (专利号：ZL201811535397.9)；申请日：2018-12-14；授权日：2019-08-27

4.一种微量输注装置. 首都医科大学附属北京天坛医院，北京市神经外科研究所. 王成尉，刘福生，彭士荣 （专利号：ZL201921932385.X）；申请日：2019-11-08；授权日：2020-10-13

5.溶瘤病毒在葡萄膜黑色素瘤治疗上的应用、治疗效果的标记物及其检测试剂. 北京市神经外科研究所. 刘福生，刘思思，张俊文（申请号：202010784288.1）

6.一种重组溶瘤病毒及其制备方法和应用. 北京市神经外科研究所. 刘福生，张俊文（专利号：ZL202110220936.5）；申请时间：2021-02-26；授权时间：2022-03-23

7.一种用于治疗肿瘤的药物组合及其应用. 首都医科大学附属北京同仁医院, 北京市神经外科研究所. 刘思思, 张俊文, 刘福生（申请号：202210070908.4）

专著：刘福生; 金贵善; 脑胶质瘤基础与临床研究, 人民卫生出版社, 634千字, 2016.